Biotech company Elegen has been making strides in the laboratory–and it is passing the gains onto its customers. Boosted by an increase in efficiency at its advanced cell-free cloning facility thanks to automation and machine learning, the company recently announced a 25 percent cut in the price of its ENFINIA DNA product.
The announcement came on the heels of the January launch for ENFINIA DNA Plasmid, designed as a faster, cost-effective solution for clonal synthesis of long and complex genes. With this product, Elegen provides access to high-complexity clonal genes up to 15 kb, NGS-verified and shipped globally from Elegen’s U.S. facilities in just 10 business days.
The launch of ENFINIA DNA Plasmid was abetted by a $35 million Series B fundraising round in May 2024 led by Triatomic Capital. Also joining the round were strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron.
